Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss the importance of biomarker testing in non–small cell lung cancer and tools for detecting HER2-mutant disease.
Back
Tailoring Treatment Strategies and Sequencing in HER2-Mutant Advanced NSCLC
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, highlight evolving treatment approaches for HER2-mutated non–small cell lung cancer.
Tailoring Treatment Strategies and Sequencing in HER2-Mutant Advanced NSCLC
Episodes
All
All
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss frontline therapy approaches in HER2-mutant non–small cell lung cancer and the evolving role of chemoimmunotherapy.
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss factors that inform sevabertinib and zongertinib treatment selection in HER2-mutant NSCLC.
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss toxicity management with TKIs in HER2-mutant non–small cell lung cancer.
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, examine sequencing considerations between tyrosine kinase inhibitors and antibody-drug conjugates in HER2-mutant non–small cell lung cancer.
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss how the NCCN Guidelines can help supplement HER2-mutant non–small cell lung cancer management decisions.
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss other potential treatment avenues to explore in HER2-mutant non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5